Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PHR
PHR logo

PHR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
9.570
Open
9.440
VWAP
9.21
Vol
472.46K
Mkt Cap
583.93M
Low
8.990
Amount
4.35M
EV/EBITDA(TTM)
17.55
Total Shares
60.76M
EV
607.76M
EV/OCF(TTM)
7.71
P/S(TTM)
1.21
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
Show More

Events Timeline

(ET)
2026-03-31
16:30:00
Dow Jones Index Rises 2.49% to 46,341.51
select
2026-03-31
12:00:00
Major Averages Surge, S&P 500 and Nasdaq Weakest Since 2022
select

News

Globenewswire
7.0
05-12Globenewswire
Pomerantz LLP Investigates Phreesia for Securities Fraud
  • Investigation Launched: Pomerantz LLP is investigating Phreesia, Inc. and its executives for potential securities fraud or other unlawful business practices, highlighting concerns for investor rights.
  • Financial Warning: On March 30, 2026, Phreesia announced a revenue guidance reduction for fiscal year 2027, primarily due to weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment, indicating significant market challenges.
  • Stock Price Plunge: Following the financial warning, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, reflecting investor anxiety regarding the company's outlook.
  • Potential Legal Action: The investigation by Pomerantz LLP could lead to a class action lawsuit, further impacting Phreesia's market reputation and shareholder confidence, indicating potential risks in the company's compliance and transparency.
PRnewswire
7.0
05-07PRnewswire
Pomerantz LLP Investigates Phreesia for Securities Fraud
  • Securities Fraud Investigation: Pomerantz LLP is investigating claims against Phreesia, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
  • Declining Financial Performance: On March 30, 2026, Phreesia announced its financial results for Q4 and the fiscal year ending January 31, 2026, while also reducing its revenue guidance for FY 2027 due to weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment.
  • Stock Price Plunge: Following the financial warning, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, reflecting strong market concerns about the company's future prospects.
  • Potential Legal Action: Investors are advised to contact Pomerantz LLP to join the class action, indicating a severe erosion of market confidence in the company's governance and financial transparency, which may lead to further legal actions.
PRnewswire
7.0
05-01PRnewswire
Pomerantz LLP Investigates Phreesia for Securities Fraud
  • Securities Fraud Investigation: Pomerantz LLP is investigating whether Phreesia and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors and highlight potential governance risks within the company.
  • Declining Financial Performance: Phreesia's financial results announced on March 30, 2026, revealed a reduction in revenue guidance for fiscal year 2027, primarily due to weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment, indicating substantial market challenges ahead.
  • Stock Price Plunge: Following the earnings report, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, reflecting investor concerns regarding the company's future prospects and operational stability.
  • Potential Legal Action: The investigation by Pomerantz LLP may lead to a class action lawsuit, and if fraud is confirmed, it could have profound implications for Phreesia's reputation and future financing capabilities, necessitating close monitoring of developments by investors.
Globenewswire
7.0
04-08Globenewswire
Phreesia Under Investigation, Shares Plummet
  • Legal Investigation Launched: The Schall Law Firm has announced an investigation into Phreesia, focusing on potential violations of securities laws, including false or misleading statements, which could significantly impact the company's reputation and stock price if substantiated.
  • Financial Warning Issued: In its Q4 2026 financial results released on March 30, Phreesia lowered its revenue guidance for FY 2027, primarily due to weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment, highlighting the challenges the company faces in the market.
  • Stock Price Reaction: Following the financial warning and investigation news, Phreesia's shares plummeted sharply, reflecting investor concerns about the company's future performance and potentially prompting more investors to seek legal recourse.
  • Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for free legal consultations, demonstrating a commitment to protecting investor rights, which may lead to increased collective lawsuits.
Marketbeat
9.5
04-02Marketbeat
Phreesia Reaches Low Point in Q1: Recovery Expected, Timing Unclear
  • Company Performance: Phreesia, Inc. has faced stock price struggles over the past four years, primarily due to challenges stemming from its growth funded by share counts and debt, despite a strong revenue increase in Q2 2026 following a guidance update.

  • Market Outlook: The healthcare technology sector is undergoing significant changes, with expectations of doubling the total addressable market in the next eight years, which could lead to Phreesia outpacing its projected growth.

  • Recent Earnings: In its latest earnings report, Phreesia reported a net revenue of $127.07 million, marking a 16% increase from the previous year, driven by a rise in clients and revenue per client, although it missed earnings targets slightly.

  • Investment Sentiment: Despite a recent decline in stock prices, institutional buying has increased, indicating strong support for the stock, with expectations that visibility will improve as fiscal progress continues, potentially leading to a more favorable outlook.

NASDAQ.COM
4.5
03-31NASDAQ.COM
US Stocks Surge on Hopes for End to Iran War
  • Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
  • Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
  • Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
  • Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
Wall Street analysts forecast PHR stock price to rise
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
24.00
Averages
29.09
High
35.00
Current: 0.000
sliders
Low
24.00
Averages
29.09
High
35.00
KeyBanc
Overweight
downgrade
$15 -> $12
AI Analysis
2026-04-13
Reason
KeyBanc
Price Target
$15 -> $12
AI Analysis
2026-04-13
downgrade
Overweight
Reason
KeyBanc lowered the firm's price target on Phreesia to $12 from $15 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup is largely positive, with beats likely across the group. That said, KeyBanc thinks most companies will reiterate their full-year guidance given the uncertain macro. Thematically, it believes healthcare systems are continuing to see good utilization, supporting capex/ software spend, and Pharma digital advertising environment remains choppy.
Wells Fargo
Overweight
to
NULL
downgrade
$25 -> $15
2026-04-05
Reason
Wells Fargo
Price Target
$25 -> $15
2026-04-05
downgrade
Overweight
to
NULL
Reason
Wells Fargo lowered the firm's price target on Phreesia to $15 from $25 and keeps an Overweight rating on the shares. The company's fiscal 2027 revenue outlook "decelerated sharply," but appears mainly Network-driven, the analyst tells investors in a research note. Wells cites valuation compression and Phreesia's decelerated growth outlook for the target cut. The firm notes that its recent Network channel checks were constructive.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PHR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Phreesia Inc (PHR.N) is 18.48, compared to its 5-year average forward P/E of -1.98. For a more detailed relative valuation and DCF analysis to assess Phreesia Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.98
Current PE
18.48
Overvalued PE
188.00
Undervalued PE
-191.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-27.06
Current EV/EBITDA
15.78
Overvalued EV/EBITDA
92.81
Undervalued EV/EBITDA
-146.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.84
Current PS
1.07
Overvalued PS
8.70
Undervalued PS
0.97

Financials

AI Analysis
Annual
Quarterly

Whales Holding PHR

D
Deerfield Management Company, L.P.
Holding
PHR
+10.27%
3M Return
G
Granahan Investment Management, LLC
Holding
PHR
+5.42%
3M Return
R
Rock Springs Capital Management LP
Holding
PHR
+3.75%
3M Return
G
Greenhouse Funds LLLP
Holding
PHR
-6.84%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Phreesia Inc (PHR) stock price today?

The current price of PHR is 9.08 USD — it has decreased -5.52

What is Phreesia Inc (PHR)'s business?

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

What is the price predicton of PHR Stock?

Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is29.09 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Phreesia Inc (PHR)'s revenue for the last quarter?

Phreesia Inc revenue for the last quarter amounts to 127.07M USD, increased 15.85

What is Phreesia Inc (PHR)'s earnings per share (EPS) for the last quarter?

Phreesia Inc. EPS for the last quarter amounts to 0.02 USD, decreased -118.18

How many employees does Phreesia Inc (PHR). have?

Phreesia Inc (PHR) has 1789 emplpoyees as of May 13 2026.

What is Phreesia Inc (PHR) market cap?

Today PHR has the market capitalization of 583.93M USD.